Description: OncoZenge AB (publ), a pharmaceutical company, develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden.
Home Page: www.oncozenge.se
Gustavslundsvagen 34
Bromma,
167 51
Sweden
Phone:
46 8 31 14 20
Officers
| Name | Title |
|---|---|
| Mr. Paul de Potocki M.Sc. | Chief Exec. Officer |
| Mr. Mark Beveridge | Chief Financial Officer |
| Ms. Pirkko Sulila Tamsen | Chief Operating Officer |
| Dr. Markus Jerling M.D., Ph.D. | Chief Medical Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6667 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |